Submit your email to push it up the queue
Syneos Health US, Inc., a leading biopharmaceutical solutions organisation, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2018 through the merger of INC Research and inVentiv Health, the company has quickly established itself in the clinical research and commercialisation sectors. Specialising in integrated biopharmaceutical solutions, Syneos Health offers a unique combination of clinical development and commercial services, enabling clients to accelerate the delivery of innovative therapies to market. Their commitment to a patient-centric approach and advanced technology sets them apart in a competitive landscape. With a strong market position, Syneos Health has achieved notable milestones, including recognition for its innovative strategies in clinical trial management and patient engagement. The company continues to drive advancements in the healthcare industry, making significant contributions to the success of its partners.
How does Syneos Health US, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Syneos Health US, Inc.'s score of 41 is higher than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Syneos Health US, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Syneos Health, Inc., which may influence its climate commitments and initiatives. As of now, there are no documented reduction targets or significant climate pledges reported for Syneos Health US, Inc. However, it is important to note that the company inherits its climate initiatives from its parent organisation, Syneos Health, Inc. This includes participation in various climate-related initiatives such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), although specific targets or achievements have not been disclosed. In the absence of specific emissions data, it is clear that Syneos Health US, Inc. is part of a broader corporate commitment to addressing climate change through inherited initiatives from its parent company. Further details on their climate strategy and performance may be available through Syneos Health, Inc.
Access structured emissions data, company-specific emission factors, and source documents
2023 | 2024 | |
---|---|---|
Scope 1 | 16,298,000 | 00,000,000 |
Scope 2 | 9,704,000 | 0,000,000 |
Scope 3 | 261,804,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Syneos Health US, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.